Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > ARCHIVE
ARCHIVE
- Kenporen Expects Record-High Deficit of ¥523.5 Bil. in FY2009
October 4, 2010
- Osteogenesis Promoter Forteo: Eli Lilly
October 4, 2010
- GLP-1 Agonist Liraglutide More Effective Than Sitagliptin:
October 4, 2010
- Sanofi-aventis Starts Multinational PIV ATLAS Study for Lantus
October 4, 2010
- Volibris for Oral Treatment of PAH: GSK
October 4, 2010
- Meta-Analysis Shows Greater Effects of GLP-1 Analogues on HbA1c and Weight
October 4, 2010
- Mylan Opens 24-Hour Customer Support Center
October 4, 2010
- Japan's 5th Biologic for RA Orencia: Bristol Myers
October 4, 2010
- Alogliptin Effectively Reduces HbA1c in Combination with Other Antidiabetic Agents
October 4, 2010
- JAOG Requests Public Funding for HTLV-1 Screening in Pregnancy
October 4, 2010
- Albumin-Bound Paclitaxel Abraxan: Taiho
October 4, 2010
- Lixisenatide Significantly Reduces HbA1c but Not Weight
October 4, 2010
- Meiji HD to Create Meiji Seika Pharma in April 2011
October 4, 2010
- 1,021 HIV-Infected Cases Reported in 2009: Korosho AIDS Survey
October 4, 2010
- Cancer Pain Relieving Agent Tramal: Nippon Shinyaku
October 4, 2010
- BI's SGLT-2 Inhibitor Reduces Both HbA1c and Weight
October 4, 2010
- Kissei Licenses Drug for yperphosphatemia from Vifor Pharma
October 4, 2010
- 19 Products Added to NHI Price List
October 4, 2010
- Dapagliflozin Non-Inferior to SU
October 4, 2010
- Takeda to Construct New Formulation Plant in Hikari
October 4, 2010
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…